Obstetric Management

Inherited Bleeding Disorders in Women

Volumn , Issue , 2009, Pages 124-150

  Chi, Claudia ^a   Kadir, Rezan A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antenatal management; Carriers of hemophilia; Childbirth intrinsic hemostatic challenge to women with inherited bleeding disorders; Hemostatic changes in pregnancy; Inherited fibrinogen abnormalities; Intrapartum and postpartum management; Obstetric management; Prothrombin deficiency rarest inherited bleeding; Rare bleeding disorders; VWD associated with increased risk of miscarriage

Indexed keywords

EID: 84889619546     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303490.ch10     Document Type: Chapter

References (196)

1. Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12: 141-154.
2. Beller FK, Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur J Obstet Gynecol Reprod Biol 1982; 13: 177- 197.
3. Stirling Y, Woolf L, North WR, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
4. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166- 1170.
5. Kjellberg U, Andersson NE, Rosen S, et al. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999; 81: 527-531.
6. Donohoe S, Quenby S, Mackie I, et al. Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal and heparintreated antiphospholipid syndrome pregnancies. Lupus 2002; 11: 11-20.
7. Uchikova EH, Ledjev II. Changes in haemostasis during normal pregnancy. Eur J Obstet Gynecol Reprod Biol 2005; 119: 185-188.
8. Condie RG. A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre-eclampsia. Br J Obstet Gynaecol 1976; 83: 636-639.
9. Dalaker K. Clotting factor VII during pregnancy, delivery and puerperium. Br J Obstet Gynaecol 1986; 93: 17-21.
10. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 153-168.
11. Nilsson IM, Kullander S. Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynecol Scand 1967; 46: 273-285.
12. Phillips LL, Rosano L, Skrodelis V. Changes in factor XI (plasma thromboplastin antecedent) levels during pregnancy. Am J Obstet Gynecol 1973; 116: 1114-1116.
13. Nossel HL, Lanzkowsky P, Levy S, et al. A study of coagulation factor levels in women during labour and in their newborn infants. Thromb Diath Haemorrh 1966; 16: 185-197.
14. Coopland A, Alkjaersig N, Fletcher AP. Reduction in plasma factor 13 (fibrin stabilizing factor) concentration during pregnancy. J Lab Clin Med 1969; 73: 144-153.
15. van Wersch JW, Vooijs ME, Ubachs JM. Coagulation factor XIII in pregnant smokers and non-smokers. Int J Clin Lab Res 1997; 27: 68-71.
16. Inbal A, Muszbek L. Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003; 29: 171-174.
17. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease. Thromb Res 2007; 120 (Suppl 1): S17-S20.
18. Ramsahoye BH, Davies SV, Dasani H, Pearson JF. Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a review of the literature. Haemophilia 1995; 1: 140-144.
19. Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract Res Clin Haematol 2001; 14: 381-399.
20. Hanna W, McCarroll D, McDonald T, et al. Variant von Willebrand's disease and pregnancy. Blood 1981; 58: 873-879.
21. Kadir RA, Economides DL, Braithwaite J, et al. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997; 104: 803-810.
22. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991; 98: 909-918.
23. Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105: 314- 321.
24. Chediak JR, Alban GM, Maxey B. von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. Am J Obstet Gynecol 1986; 155: 618-624.
25. Adashi EY. Lack of improvement in von Willebrand's disease during pregnancy. N Engl J Med 1980; 303: 1178.
26. Castaman G, Eikenboom JC, Contri A, Rodeghiero F. Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F. Thromb Haemost 2000; 84: 351- 352.
27. Caliezi C, Tsakiris DA, Behringer H, et al. Two consecutive pregnancies and deliveries in a patient with von Willebrand's disease type 3. Haemophilia 1998; 4: 845-849.
28. Conti M, Mari D, Conti E, et al. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68: 282-285.
29. Castaman G, Federici AB, Bernardi M, et al. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect. J Thromb Haemost 2006; 4: 357-360.
30. Kujovich JL. von Willebrand disease and pregnancy. J Thromb Haemost 2005; 3: 246-253.
31. Watanabe T, Minakami H, Sakata Y. Successful management of pregnancy in a patient with von Willebrand disease Normandy. Obstet Gynecol 1997; 89: 859.
32. Dennis MW, Clough V, Toh CH. Unexpected presentation of type 2N von Willebrand disease in pregnancy. Haemophilia 2000; 6: 696-697.
33. Nishino M, Nishino S, Sugimoto M, et al. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy. Int J Hematol 1996; 64: 127-134.
34. Castaman G, Bertoncello K, Bernardi M, Rodeghiero F. Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease. J Thromb Haemost 2005; 3: 391-392.
35. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 2032-2038.
36. Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease. Blood 1987; 69: 786-789.
37. Casonato A, Sartori MT, Bertomoro A, et al. Pregnancy-induced worsening of thrombocytopenia in a patient with type IIB von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2: 33-40.
38. Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy. Br J Haematol 1987; 67: 349-353.
39. Ieko M, Sakurama S, Sagawa A, et al. Effect of a factor VIII concentrate on type IIB von Willebrand's disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers. Am J Hematol 1990; 35: 26-31.
40. Mathew P, Greist A, Maahs JA, et al. Type 2B vWD: the varied clinical manifestations in two kindreds. Haemophilia 2003; 9: 137-144.
41. Burlingame J, McGaraghan A, Kilpatrick S, et al. Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2. Am J Obstet Gynecol 2001; 184: 229-230.
42. Konje JC, Murphy P, de Chazal R, et al. Severe factor X deficiency and successful pregnancy. Br J Obstet Gynaecol 1994; 101: 910-911.
43. Bofill JA, Young RA, Perry KG, Jr. Successful pregnancy in a woman with severe factor X deficiency. Obstet Gynecol 1996; 88: 723.
44. Rizk DE, Castella A, Shaheen H, Deb P. Factor VII deficiency detected in pregnancy: a case report. Am J Perinatol 1999; 16: 223-226.
45. Robertson LE, Wasserstrum N, Banez E, et al. Hereditary factor VII deficiency in pregnancy: peripartum treatment with factor VII concentrate. Am J Hematol 1992; 40: 38-41.
46. Braun MW, Triplett DA. Case Report: Factor VII deficiency in an obstetrical patient. J Indiana State Med Assoc 1979; 72: 900-902.
47. Eskandari N, Feldman N, Greenspoon JS. Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstet Gynecol 2002; 99: 935-937.
48. Kulkarni AA, Lee CA, Kadir RA. Pregnancy in women with congenital factor VII deficiency. Haemophilia 2006; 12: 413-416.
49. Myers B, Pavord S, Kean L, et al. Pregnancy outcome in Factor XI deficiency: incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. Br J Obstet Gynaecol 2007; 114: 643-646.
50. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders - review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
51. Kobayashi T, Kanayama N, Tokunaga N, et al. Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 2000; 109: 364-366.
52. Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000; 55: 103-108.
53. Gilabert J, Reganon E, Vila V, et al. Congenital hypofibrinogenemia and pregnancy, obstetric and hematological management. Gynecol Obstet Invest 1987; 24: 271-276.
54. Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstet Gynecol Surv 2007; 62: 255-260.
55. Chi C, Lee CA, Shiltagh N, et al. Pregnancy in carriers of haemophilia. Haemophilia 2008; 14: 56-64.
56. Guy GP, Baxi LV, Hurlet-Jensen A, Chao CR. An unusual complication in a gravida with factor IX deficiency: case report with review of the literature. Obstet Gynecol 1992; 80: 502-505.
57. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382.
58. Sipila P, Hartikainen-Sorri AL, Oja H, Von Wendt L. Perinatal outcome of pregnancies complicated by vaginal bleeding. Br J Obstet Gynaecol 1992; 99: 959-963.
59. Axelsen SM, Henriksen TB, Hedegaard M, Secher NJ. Characteristics of vaginal bleeding during pregnancy. Eur J Obstet Gynecol Reprod Biol 1995; 63: 131-134.
60. Yang J, Savitz DA, Dole N, et al. Predictors of vaginal bleeding during the first two trimesters of pregnancy. Paediatr Perinat Epidemiol 2005; 19: 276-283.
61. Kirtava A, Drews C, Lally C, et al. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003; 9: 292-297.
62. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320: 1708-1712.
63. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ 1997; 315: 32-34.
64. Blohm F, Friden B, Milsom I. A prospective longitudinal population-based study of clinical miscarriage in an urban Swedish population. Br J Obstet Gynaecol 2008; 115: 176-182.
65. Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 784-790.
66. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-1239.
67. Ito M, Yoshimura K, Toyoda N, Wada H. Pregnancy and delivery in patients with von Willebrand's disease. J Obstet Gynaecol Res 1997; 23: 37-43.
68. Punnonen R, Nyman D, Gronroos M, Wallen O. Von Willebrand's disease and pregnancy. Acta Obstet Gynecol Scand 1981; 60: 507-509.
69. Sorosky J, Klatsky A, Nobert GF, Burchell RC. Von Willebrand's disease complicating second-trimester abortion. Obstet Gynecol 1980; 55: 253-254.
70. James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007; 5: 1165-1169.
71. Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 218-231.
72. Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders - review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12: 301-336.
73. Fisher S, Rikover M, Naor S. Factor 13 deficiency with severe hemorrhagic diathesis. Blood 1966; 28: 34-39.
74. Boda Z, Pfliegler G, Muszbek L, et al. Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A case report. Haemostasis 1989; 19: 348-352.
75. Lak M, Peyvandi F, Ali SA, et al. Pattern of symptoms in Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1: 1852-1853.
76. Padmanabhan LD, Mhaskar R, Mhaskar A, Ross CR. Factor XIII deficiency: a rare cause of repeated abortions. Singapore Med J 2004; 45: 186-187.
77. Inbal A, Kenet G. Pregnancy and surgical procedures in patients with factor XIII deficiency. Biomed Prog 2003; 16: 69-71.
78. Rodeghiero F, Castaman GC, Di Bona E, et al. Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case. Blut 1987; 55: 45-48.
79. Kobayashi T, Terao T, Kojima T, et al. Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery. Gynecol Obstet Invest 1990; 29: 235-238.
80. Trehan AK, Fergusson IL. Congenital afibrinogenaemia and successful pregnancy outcome. Case report. Br J Obstet Gynaecol 1991; 98: 722-724.
81. Evron S, Anteby SO, Brzezinsky A, et al. Congenital afibrinogenemia and recurrent early abortion: a case report. Eur J Obstet Gynecol Reprod Biol 1985; 19: 307-311.
82. Lak M, Keihani M, Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107: 204-206.
83. Girolami A, Sartori MT, Simioni P. An updated classification of factor XIII defect. Br J Haematol 1991; 77: 565-566.
84. Asahina T, Kobayashi T, Okada Y, et al. Studies on the role of adhesive proteins in maintaining pregnancy. Horm Res 1998; 50 (Suppl 2): 37-45.
85. Goodwin TM. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989; 44: 157-161.
86. Ness PM, Budzynski AZ, Olexa SA, Rodvien R. Congenital hypofibrinogenemia and recurrent placental abruption. Obstet Gynecol 1983; 61: 519-523.
87. Kobayashi T, Asahina T, Maehara K, et al. Congenital afibrinogenemia with successful delivery. Gynecol Obstet Invest 1996; 42: 66-69.
88. Inamoto Y, Terao T. First report of case of congenital afibrinogenemia with successful delivery. Am J Obstet Gynecol 1985; 153: 803-804.
89. Grech H, Majumdar G, Lawrie AS, Savidge GF. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature. Br J Haematol 1991; 78: 571-572.
90. Matsuno K, Mori K, Amikawa H. A case of congenital afibrinogenemia with abortion, intracranial hemorrhage and peritonitis. Jpn J Clin Hematol 1977; 18: 1438.
91. Dube B, Agarwal SP, Gupta MM, Chawla SC. Congenital deficiency of fibrinogen in two sisters. A clinical and haematological study. Acta Haematol 1970; 43: 120-127.
92. Roque H, Stephenson C, Lee MJ, et al. Pregnancyrelated thrombosis in a woman with congenital afibrinogenemia: a report of two successful pregnancies. Am J Hematol 2004; 76: 267-270.
93. Frenkel E, Duksin C, Herman A, Sherman DJ. Congenital hypofibrinogenemia in pregnancy: report of two cases and review of the literature. Obstet Gynecol Surv 2004; 59: 775-779.
94. Aygoren-Pursun E, Martinez Sauger I, Rusicke E, et al. Retrochorionic hematoma in congenital afibrinogenemia: resolution with fibrinogen concentrate infusions. Am J Hematol 2007; 82: 317-320.
95. Dupuy E, Soria C, Molho P, et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-219.
96. Chafa O, Chellali T, Sternberg C, et al. Severe hypofibrinogenemia associated with bilateral ischemic necrosis of toes and fingers. Blood Coagul Fibrinolysis 1995; 6: 549-552.
97. Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90.
98. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-161.
99. Takala T, Oksa H, Rasi V, Tuimala R. Dysfibrinogenemia associated with thrombosis and third-trimester fetal loss. A case report. J Reprod Med 1991; 36: 410-412.
100. Edwards RZ, Rijhsinghani A. Dysfibrinogenemia and placental abruption. Obstet Gynecol 2000; 95: 1043.
101. Yamanaka Y, Takeuchi K, Sugimoto M, et al. Dysfibrinogenemia during pregnancy treated successfully with fibrinogen. Acta Obstet Gynecol Scand 2003; 82: 972-973.
102. Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82: 1207-1214.
103. Girolami A, Scarano L, Saggiorato G, et al. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis 1998; 9: 557-569.
104. Catanzarite VA, Novotny WF, Cousins LM, Schneider JM. Pregnancies in a patient with congenital absence of prothrombin activity: case report. Am J Perinatol 1997; 14: 135-138.
105. Girolami A, Scandellari R, Lombardi AM, et al. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and heterozygotes) and review of the literature. Haemophilia 2005; 11: 26-30.
106. Noia G, De Carolis S, De Stefano V, et al. Factor V deficiency in pregnancy complicated by Rh immunization and placenta previa. A case report and review of the literature. Acta Obstet Gynecol Scand 1997; 76: 890-892.
107. Fadel HE, Krauss JS. Factor VII deficiency and pregnancy. Obstet Gynecol 1989; 73: 453-454.
108. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243- 1252.
109. Peyvandi F, Mannucci PM, Lak M, et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol 1998; 102: 626-628.
110. Knight RD, Barr CF, Alving BM. Replacement therapy for congenital Factor X deficiency. Transfusion 1985; 25: 78-80.
111. Girolami A, Randi ML, Ruzzon E, et al. Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K-dependent coagulation factors. Acta Haematol 2006; 115: 58-63.
112. Kumar M, Mehta P. Congenital coagulopathies and pregnancy: report of four pregnancies in a factor Xdeficient woman. Am J Hematol 1994; 46: 241-244.
113. Girolami A, Lazzarin M, Scarpa R, Brunetti A. Further studies on the abnormal factor X (factor X Friuli) coagulation disorder: a report of another family. Blood 1971; 37: 534-541.
114. Larrain C. [Congenital blood coagulation factor X deficiency. Successful result of the use prothrombin concentrated complex in the control of ++cesarean section hemorrhage in 2 pregnancies]. Rev Med Chil 1994; 122: 1178-1183.
115. Romagnolo C, Burati S, Ciaffoni S, et al. Severe factor X deficiency in pregnancy: case report and review of the literature. Haemophilia 2004; 10: 665-668.
116. Seligsohn U. Factor XI deficiency. Thromb Haemost 1993; 70: 68-71.
117. Peyvandi F, Lak M, Mannucci PM. Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica 2002; 87: 512-514.
118. Rapaport SI, Proctor RR, Patch MJ, Yettra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18: 149-165.
119. Leiba H, Ramot B, Many A. Heredity and coagulation studies in ten families with Factor XI (plasma thromboplastin antecedent) deficiency. Br J Haematol 1965; 11: 654-665.
120. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, et al. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69: 521-528.
121. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds - a clinical and laboratory study. Thromb Haemost 1995; 73: 194-202.
122. Ragni MV, Sinha D, Seaman F, et al. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood 1985; 65: 719-724.
123. Salomon O, Steinberg DM, Tamarin I, et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16: 37-41.
124. Bolton-Maggs PH. The management of factor XI deficiency. Haemophilia 1998; 4: 683-688.
125. McMahon MJ, James AH. Combined deficiency of factors II, VII, IX, and X (Borgschulte-Grigsby deficiency) in pregnancy. Obstet Gynecol 2001; 97: 808-809.
126. Rane SM, Guirgis RR, Higgins B, Nicolaides KH. Models for the prediction of successful induction of labor based on pre-induction sonographic measurement of cervical length. J Matern Fetal Neonatal Med 2005; 17: 315-322.
127. Pachydakis A, Belgaumkar P, Sharmah A. Persistent scalp bleeding due to fetal coagulopathy following fetal blood sampling. Int J Gynaecol Obstet 2006; 92: 69-70.
128. Hull MG, Wilson JA. Massive scalp haemorrhage after fetal blood sampling due to haemorrhagic disease. BMJ 1972; 4: 321-322.
129. Reti LL, Adey FD, Brown MF. Excessive bleeding from fetal scalp blood sampling. Aust N Z J Obstet Gynaecol 1980; 20: 55-57.
130. Ljung R, Lindgren AC, Petrini P, Tengborn L. Normal vaginal delivery is to be recommended for haemophilia carrier gravidae. Acta Paediatr 1994; 83: 609-611.
131. Kulkarni R, Lusher JM, Henry RC, Kallen DJ. Current practices regarding newborn intracranial haemorrhage and obstetrical care and mode of delivery of pregnant haemophilia carriers: a survey of obstetricians, neonatologists and haematologists in the United States, on behalf of the National Hemophilia Foundation's Medical and Scientific Advisory Council. Haemophilia 1999; 5: 410-415.
132. Michaud JL, Rivard GE, Chessex P. Intracranial hemorrhage in a newborn with hemophilia following elective cesarean section. Am J Pediatr Hematol Oncol 1991; 13: 473-475.
133. AbouZahr C. Global burden of maternal death and disability. Br Med Bull 2003; 67: 1-11.
134. El Refaey H, Rodeck C. Post-partum haemorrhage: definitions, medical and surgical management. A time for change. Br Med Bull 2003; 67: 205-217.
135. Hoveyda F, MacKenzie IZ. Secondary postpartum haemorrhage: incidence, morbidity and current management. Br J Obstet Gynaecol 2001; 108: 927-930.
136. Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour. Cochrane Database Syst Rev 2000; CD000007.
137. Gulmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2007; CD000494.
138. Khan RU, El Refaey H. Pharmacokinetics and adverseeffect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol 2003; 101: 968-974.
139. Hofmeyr GJ, Walraven G, Gulmezoglu AM, et al. Misoprostol to treat postpartum haemorrhage: a systematic review. Br J Obstet Gynaecol 2005; 112: 547-553.
140. Kulkarni A, Riddell A, Lee CA, Kadir RA Assessment of factor VIII and von Willebrand factor levels in cord blood. RCOG 6th International Scientific Meeting, 27-30 September 2005, Cairo, Egypt.
141. Lyon MF. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet 1962; 14: 135-148.
142. Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, et al. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59: 349-352.
143. Yang MY, Ragni MV. Clinical manifestations and management of labor and delivery in women with factor IX deficiency. Haemophilia 2004; 10: 483-490.
144. Walker ID, Walker JJ, Colvin BT, et al. Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force. J Clin Pathol 1994; 47: 100-108.
145. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders: a United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) Guideline approved by the British Committee for standards in Haematology. Haemophilia 2008; 14; 671-684.
146. Kouides PA, Phatak PD, Burkart P, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia 2000; 6: 643-648.
147. Lipton RA, Ayromlooi J, Coller BS. Severe von Willebrand's disease during labor and delivery. JAMA 1982; 248: 1355-1357.
148. Roque H, Funai E, Lockwood CJ. von Willebrand disease and pregnancy. J Matern Fetal Med 2000; 9: 257-266.
149. Menache D. Congenital fibrinogen abnormalities. Ann N Y Acad Sci 1983; 408: 121-130.
150. Strickland DM, Galey WT, Hauth JC. Hypofibrinogenemia as a cause of delayed postpartum hemorrhage. Am J Obstet Gynecol 1982; 143: 230-231.
151. Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103: 1067-1069.
152. Fajardo LF, Silvert D. Pregnancy and Ac-globulin deficiency; report of a case. Am J Obstet Gynecol 1957; 74: 909-914.
153. Triplett DA, Brandt JT, Batard MA, et al. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66: 1284-1287.
154. Jimenez-Yuste V, Villar A, Morado M, et al. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia 2000; 6: 588-590.
155. de Sousa C, Clark T, Bradshaw A. Antenatally diagnosed subdural haemorrhage in congenital factor X deficiency. Arch Dis Child 1988; 63: 1168-1170.
156. Rezig K, Diar N, Benabidallah D, Audibert J. [Factor X deficiency and pregnancy]. Ann Fr Anesth Reanim 2002; 21: 521-524.
157. Bolton-Maggs PH, Colvin BT, Satchi BT, et al. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344: 748-749.
158. O'Connell NM, Riddell AF, Pascoe G, et al. Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia 2008; 14: 775-781.
159. Lawler P, White B, Pye S, et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8(2): 145-148.
160. Bern MM, Sahud M, Zhukov O, et al. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia 2005; 11: 20-25.
161. Mannucci PM, Bauer KA, Santagostino E, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84: 1314-1319.
162. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7: 229-242.
163. Fukue H, Arai M. Factor XIIIA subunit deficiency. Jpn J Thromb Hemost 2001; 12: 66-73.
164. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351: 683-694.
165. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-2521.
166. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53: 450-455.
167. Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 7: 235-241.
168. Sanchez-Luceros A, Meschengieser SS, Turdo K, et al. Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history. Thromb Res 2007; 120: 387-390.
169. Ruggeri ZM, Mannucci PM, Lombardi R, et al. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982; 59: 1272-1278.
170. Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol 1995; 89: 147-151.
171. Holmberg L, Nilsson IM, Borge L, et al. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med 1983; 309: 816-821.
172. Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N ("Normandy") von Willebrand disease. Collaborative Group. Br J Haematol 1994; 88: 849-854.
173. Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl 1987; 137: 22-25.
174. Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993; 70: 238-240.
175. Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 1: in major surgery. Drug Safety 2008; 31(3): 217-230.
176. Rainsford SG, Jouhar AJ, Hall A. Tranexamic acid in the control of spontaneous bleeding in severe haemophilia. Thromb Diath Haemorrh 1973; 30: 272-279.
177. Forbes CD, Barr RD, Reid G, et al. Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. BMJ 1972; 2: 311-313.
178. Berliner S, Horowitz I, Martinowitz U, et al. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis 1992; 3: 465-468.
179. Fodstad H, Liliequist B. Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases. Acta Neurochir (Wien) 1979; 49: 129-144.
180. Rydin E, Lundberg PO. Letter: Tranexamic acid and intracranial thrombosis. Lancet 1976; 2: 49.
181. Davies D, Howell DA. Tranexamic acid and arterial thrombosis. Lancet 1977; 1: 49.
182. Pabinger I, Grafenhofer H. Thrombosis during pregnancy: risk factors, diagnosis and treatment. Pathophysiol Haemost Thromb 2002; 32: 322-324.
183. Prevention of venous thrombosis and pulmonary embolism. Natl Inst Health Consens Dev Conf Consens Statement 1986; 6: 1-8.
184. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-619.
185. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-1265.
186. Walzman M, Bonnar J. Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Arch Toxicol Suppl 1982; 5: 214-220.
187. Svanberg L, Astedt B, Nilsson IM. Abruptio placentae - treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980; 59: 127-130.
188. Gai MY, Wu LF, Su QF, Tatsumoto K. Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol 2004; 112: 154-157.
189. As AK, Hagen P, Webb JB. Tranexamic acid in the management of postpartum haemorrhage. Br J Obstet Gynaecol 1996; 103: 1250-1251.
190. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary, edn. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2004.
191. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol 1996; 9: 273-290.
192. Azzi A, Ciappi S, Zakvrzewska K, et al. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 228-230.
193. Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994; 120: 1-7.
194. Lusher JM. Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP - a survey of European physicians. Haemophilia 1998; 4 Suppl 3: 11-14.
195. Stones RW, Paterson CM, Saunders NJ. Risk factors for major obstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol 1993; 48: 15-18.
196. Sheiner E, Sarid L, Levy A, et al. Obstetric risk factors and outcome of pregnancies complicated with early postpartum hemorrhage: a population-based study. J Matern Fetal Neonatal Med 2005; 18: 149-154.